Compare SOTK & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | ACRV |
|---|---|---|
| Founded | 1975 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 67.2M |
| IPO Year | 1995 | 2022 |
| Metric | SOTK | ACRV |
|---|---|---|
| Price | $5.49 | $1.96 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 45.4K | ★ 415.4K |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | 15.13 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $20,909,315.00 | N/A |
| Revenue This Year | $4.02 | N/A |
| Revenue Next Year | $10.95 | $568.17 |
| P/E Ratio | $110.40 | ★ N/A |
| Revenue Growth | ★ 1.97 | N/A |
| 52 Week Low | $3.23 | $1.20 |
| 52 Week High | $6.24 | $3.56 |
| Indicator | SOTK | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 65.74 |
| Support Level | $3.79 | $1.62 |
| Resistance Level | $5.72 | $2.02 |
| Average True Range (ATR) | 0.47 | 0.12 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 49.17 | 74.07 |
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.